Issue link: https://www.e-digitaleditions.com/i/1481708
PharmTech.com Trends in Formulation 2022 eBook Pharmaceutical Technology ® 57 refining how we serve the pharma community in the digital realm, 24 hours a day, seven days a week, 365 days a year. And now that we are moving past the COVID era at last, our focus is on the opportu- nity to further integrate our in-person event expe- rience with our online offering so that one entirely compliments the other. For example, we are running a virtual companion event six weeks prior to in-person CPHI Frankfurt called 'Connect to Frankfurt'. The virtual event gives visitors access [to] over 30 webinars covering all the key issues affecting the pharma industry right now. But the virtual environment also enables visitors to enhance their experience at the in-person CPHI Frankfurt event in November. Visitors can identify the people and companies they want to meet in person and set up meetings in advance. Our challenge is to help visitors get even more value from both the online and the face-to-face events they attend, making best use of their time to engage with vital industry content, to meet more sup- ply change partners, and to deepen their most vital industry partnerships. And of course, the virtual envi- ronment means visitors can catch up on the content sessions they missed and meet online those partners they didn't manage to meet during the show. PharmTech: What trends do you see as pivotal coming out of the pandemic? Anderson: There is a lot of talk of a global eco- nomic slowdown yet for the pharma supply chain. The forces of demand and capacity seem likely to stay strong, and growth looks pretty robust for the next two or three years. And for CDMOs [contract devel- opment and manufacturing organizations], the CPHI Annual Report 2022 points to an extremely healthy outlook. Behind these growth figures, you only need look at this year's CPHI Frankfurt agenda to get a window into the hot topics of tomorrow: with psyche- delics, new excipients, and mRNA [messenger RNA] vaccines for non-infectious disease indications to be big growth areas. And these highlights sit along- side the single biggest lesson pharma learnt from the pandemic, namely the value of collaboration and partnering. It's that learning which drives us to never rest on our laurels and to keep helping the industry to find new ways to meet, learn, and connect. It's really important to acknowledge—celebrate, even—that the partnerships established at CPHI make a real-world difference to the pharma industry in terms of how fast medicines are developed and reach the market, are accessed by prescribers, and deliver good health outcomes to patients. CPHI FrankFurt SHow GuIde More with Adam Andersen PharmTech: What brought you into your current role and what factors help create your best day at work? Anderson: I have been leading the Informa Markets Pharma portfolio for four years. Previously, I led Informa's Natural Products Expos and Supplyside Expos in the United States. Those events have a high expectation for quality events and experience, as well as a complex regulatory environment for exhibitors. The CPHI opportunity was the great next opportunity to lead a global portfolio in the dynamic pharma market. Of course, being based in Amsterdam never hurts, it's a beautiful city and welcoming country. Factors for my best day at work start with exercise and coffee! I like to get out for a run, boxing, or anything to move before getting my kids up, getting the day started. I approach everything with a growth mindset and always looking ahead to what the day holds, including defining my goals and planning ahead to what results I want to achieve each day and how our CPHI team can continue to offer incredible experiences in-person and on-demand. CPHI on Outsourcing The CPHI Frankfurt Content Team presents a summary of CPHI's The Future of Outsourcing–Strategies for Partner Se- lection report in an article published on PharmTech.com. In the article, the team provides an analysis of experts' views on best practices for selecting an outsourcing partner and how to establish "a futureproof resource". The team takes a look at the changes in discovery and development in the pharmaceutical industry and what these changes mean for timelines and expectations. The type, and amount, of contract organizations choosen by sponsors will be impacted by these changes. The impact of biotechs and aquisitions on the pharma industry is also discussed. Click HERE to read the full article. Additionally, Adam Andersen, vice president, Pharma, Informa, shares insights with Pharmaceutical Executive into the transformational changes happening within the pharma industry as a result of environmental, social, and governance agendas. In the article, At the Heart of Pharma: ESG has Arrived as a Central Strategy, Andersen points to the findings from the CPHI report, demonstrating how integral envirnomental considerations are now becoming. Click HERE to read the full article.